REG - Physiomics PLC - Result of WRAP Retail Offer

PhysiomicsAnnouncement

05/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240705:nRSE2466Va&default-theme=true

RNS Number : 2466V  Physiomics PLC  05 July 2024

Unless otherwise defined herein, the capitalised terms used in this
announcement have the same meaning as those used in the Company's
announcements released on 3 July 2024.

 

5 July 2024

 

Physiomics Plc

("Physiomics" or the "Company")

 

Result of WRAP Retail Offer

 

Physiomics plc, (AIM: PYC), is pleased to announce, further to the
announcements on 3 July 2024, the completion of the WRAP Retail Offer, at the
same issue price as the previously announced Placing (together, the
"Fundraise"). The WRAP Retail Offer, which closed at 4:30 p.m. yesterday and
which was oversubscribed, has raised gross proceeds of £25,000 through the
issue of a total of 4,166,667 new Ordinary Shares to existing retail
shareholders in the United Kingdom.

 

The Fundraise, which is conditional on Admission, raises gross proceeds of, in
aggregate, £406,417, via the issue of 63,569,573 Placing Shares pursuant to
the Placing and  4,166,667 WRAP Retail Offer Shares pursuant to the WRAP
Retail Offer.

 

Use of Proceeds

In order to further develop its business and accelerate growth, the Company
targeted a raise of £406,417  with the intention of using the net proceeds
of the fundraise towards activities including:

·    Recruitment of a Head of Mathematical Modelling Service Line to
accelerate conversion of the pipeline and drive operational excellence.

·    Further investment in Business Development and Marketing to build and
strengthen the pipeline, expand into new therapeutic areas, develop its data
science offering and launch its biostatistics offering.

·    Build a biostatistics capability, including team expansion,
development of processes, acquisition of necessary tools and exploration of
strategic options.

·    Implementation of the personalised dosing tool on the DoseMeRx
Platform, enabling it to be available to clinicians across the US and deliver
on a study in partnership with DoseMeRx to further develop the tools G-CSF
functionality.

 

Admission and Total Voting Rights

Applications have been made for the Placing Shares and the WRAP Retail Offer
Shares to be admitted to trading on AIM, which is expected to take effect and
dealings to commence at 8:00 a.m. on or around 9 July 2024 ("Admission").

 

Following Admission, the Company will have 203,208,718 Ordinary Shares in
issue. Since the Company currently holds no shares in treasury, the total
number of voting rights in the Company will be 203,208,718.These figure may be
used by shareholders of the Company as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's Disclosure Guidance
and Transparency Rules.

 

For further information, please contact:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

Winterflood Retail Access Platform

Joe Winkley & Sophia Bechev

+44 (0)20 8100 0000

 

Further information on the Company can be found on its website at
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

The Company's LEI is 213800A71DSZ6ABMTQ91.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIQKQBKDBKBDOK